TKRT(SH:688569)2022-10-16 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥409,949,043.24, a decrease of 0.59% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥79,065,948.84, an increase of 16.13% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for the year-to-date was ¥187,513,015.22, reflecting a significant increase of 93.01%[5] - Total operating revenue for the first three quarters of 2022 reached ¥1,011,087,877.27, a 24.2% increase from ¥814,624,250.54 in the same period of 2021[19] - Net profit for the first three quarters of 2022 was ¥221,801,038.25, representing a 66.5% increase compared to ¥133,276,121.15 in 2021[20] - The company reported a net profit of CNY 988,731,466.64 for the period, up from CNY 850,349,647.34, which is an increase of about 16.3%[15] - Total comprehensive income for Q3 2022 was CNY 160,150,362.50, compared to CNY 81,600,134.55 in Q3 2021, representing a significant increase[31] Earnings and Shareholder Information - The basic earnings per share for the year-to-date was ¥0.91, up 82.00% compared to the previous year[6] - Basic and diluted earnings per share for Q3 2022 were both ¥0.91, up from ¥0.50 in Q3 2021[21] - The company reported a total of 11,659 ordinary shareholders at the end of the reporting period[10] - Major shareholders include China Railway Science Research Institute Group Co., Ltd. with a 26.25% stake and Beijing Shougang Equity Investment Management Co., Ltd. with a 20.16% stake[11] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,393,153,896.91, representing a growth of 3.03% from the end of the previous year[6] - As of September 30, 2022, the total assets of Beijing Iron Science and Technology Co., Ltd. amounted to CNY 3,393,153,896.91, an increase from CNY 3,293,276,148.09 at the end of 2021, reflecting a growth of approximately 3.04%[14] - The company's current assets totaled CNY 2,600,758,296.85, slightly down from CNY 2,640,471,748.97 at the end of 2021, indicating a decrease of about 1.5%[13] - The total liabilities decreased to CNY 586,299,286.17 from CNY 655,555,900.60, representing a reduction of approximately 10.55%[15] - The total liabilities decreased to ¥447,420,953.92 from ¥540,831,827.88, a reduction of approximately 17.3%[28] - The company's equity increased to CNY 2,806,854,610.74 from CNY 2,637,720,247.49, showing an increase of about 6.43%[15] - The company's total equity increased to ¥2,244,782,400.30 from ¥2,137,298,712.80, representing a growth of approximately 5%[28] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥116,689,961.25, indicating a significant improvement in cash collection compared to the previous year[9] - Cash flow from operating activities for the first three quarters of 2022 was ¥116,689,961.25, a significant improvement from a negative cash flow of -¥58,966,467.26 in the same period of 2021[23] - Cash flow from operating activities for the first three quarters of 2022 was CNY 691,179,275.52, up from CNY 415,539,807.06 in the same period of 2021, indicating a growth of approximately 66.0%[32] - The company reported cash inflow from operating activities of CNY 664,587,692.12 in the first three quarters of 2022, compared to CNY 391,705,089.04 in the same period of 2021, reflecting a growth of approximately 69.5%[32] - The company incurred a total of ¥93,600,513.88 in cash outflows from financing activities in Q3 2022, compared to ¥27,068,504.00 in Q3 2021[24] - The company reported an investment activity cash flow net of -¥140,457,117.84 for the first three quarters of 2022, compared to -¥11,408,698.70 in the previous year[23] - Cash flow from investing activities showed a net outflow of CNY 43,973,795.14 in the first three quarters of 2022, compared to a net inflow of CNY 26,043,273.68 in the same period of 2021[32] Research and Development - Research and development expenses totaled ¥19,253,530.67 for Q3 2022, accounting for 4.70% of operating revenue, an increase of 0.53 percentage points[6] - Research and development expenses for the first three quarters of 2022 were ¥35,252,916.90, slightly up from ¥34,063,196.93 in 2021, indicating a focus on innovation[29] Inventory and Receivables - The accounts receivable rose to CNY 775,691,588.71 from CNY 660,504,810.04, marking an increase of approximately 17.4%[13] - Accounts receivable increased to ¥524,104,310.15 from ¥399,486,699.24, showing a growth of about 31.2%[26] - The inventory increased to CNY 437,813,683.24 from CNY 382,719,937.88, reflecting a growth of about 14.4%[14] - The inventory as of September 30, 2022, was ¥281,611,848.93, a slight increase from ¥272,579,610.17, reflecting a growth of about 3.5%[26] Cash and Cash Equivalents - Cash and cash equivalents decreased to CNY 1,262,994,786.99 from CNY 1,375,300,950.80, a decline of approximately 8.2%[13] - Cash and cash equivalents at the end of Q3 2022 totaled ¥1,248,164,227.26, compared to ¥981,796,033.23 at the end of Q3 2021[24] - The company's cash and cash equivalents decreased to ¥1,167,055,540.32 from ¥1,274,284,587.96, reflecting a decline of approximately 8.4%[26] - Cash and cash equivalents at the end of Q3 2022 totaled CNY 1,158,584,676.89, a decrease from CNY 1,269,480,738.67 at the beginning of the period[32] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[13] - The company did not report any cash inflow from financing activities in the first three quarters of 2022[32] - The company has not applied new accounting standards or interpretations for the year 2022[33]